Opendata, web and dolomites


Making life-saving cancer therapies more widely available by simplifying production processes, reducing costs and enhancing patient safety through its patent-protected biomimicking mesh material.

Total Cost €


EC-Contrib. €






 ImmunoGrow project word cloud

Explore the words cloud of the ImmunoGrow project. It provides you a very rough idea of what is the project "ImmunoGrow" about.

rates    round    safer    cheaper    market    genetically    natural    simplifying    anticipated    variability    lifesaving    manufacture    life    plan    significantly    structure    lab    prohibitive    input    reduce    seed    limitations    poor    cells    expensive    remission    600mn    untreatable    engineered    skilled    consumables    gold    reducing    q3    ltd    solutions    priced    publically    ing    body    activation    limited    produces    475    protected    patients    2019    independent    customers    infrastructure    treatments    immunogrow    patient    mesh    automated    83    yield    technologies    helps    trials    2021    conduct    struggling    feasibility    manufacturers    shown    8x    business    cancers    500    immune    cleanroom    seeking    2030    release    encounter    initial    mimics    sickest    healthcare    treatment    citizens    15    unless    operator    core    grey    tests    aggressive    prices    changing    capture    save    therapies    achieves    car    harness    gmt    addressable    patent    dynabeads    cell    closed    expects    labour    fund    cancer    requirement    performance    individualised    costly    standard    full   

Project "ImmunoGrow" data sheet

The following table provides information about the project.

Grey Matter Technologies Limited 

Organization address
postcode: Y21 Y5V0
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2019-10-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Grey Matter Technologies Limited IE (WEXFORD) coordinator 50˙000.00


 Project objective

Lifesaving cell-based CAR-T therapies have achieved remission rates of up to 83% for patients with the most aggressive and untreatable cancers. These therapies harness a patient’s own genetically engineered immune cells to target cancer cells. However, manufacturers are struggling to produce these individualised treatments at scale resulting in prohibitive prices as high as $475,000 per treatment. Unless solutions that address these limitations are provided, publically-funded EU healthcare systems & citizens will be priced out of these life-changing therapies.

The challenges they face include poor cell growth performance due to patient sample variability, limitations associated with equipment adopted from the research lab that require costly skilled labour, costly consumables and expensive cleanroom infrastructure.

Compared to the gold standard, Dynabeads, initial testing has shown that the ImmunoGrow technology produces an 8x higher cell yield which helps to save the sickest patients who have limited cells and significantly reduce the cost to manufacture these therapies by simplifying the process, reducing the requirement for skilled operator input and making this step both ‘closed’ and automated. ImmunoGrow achieves this through its patent-protected mesh structure that mimics the natural growth conditions cells encounter in the body.

Grey Matter Technologies (‘GMT’) Ltd. is seeking support to help fund trials with two identified customers as well to help it to conduct an independent set of tests on the product’s performance. Both these trials, as well as an associated business plan or feasibility study, will be core to the raising of a seed round of €500,000 in 2019 to further develop the technology with the release of a full-scale product anticipated for Q3 2021. GMT expects to capture 15% of the $600mn addressable T-Cell Activation market in 2030. In doing so, it will make these life changing treatments cheaper, safer and more widely available.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOGROW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOGROW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

EVERCAM (2020)

Intelligent Vision System for Improved Communication and Higher Productivity in Construction

Read More  

LTS (2020)


Read More